Eli Lilly and Company manufactures Zepbound [1].
Who makes Zepbound?
Eli Lilly and Company is the pharmaceutical company behind Zepbound, a medication approved for chronic weight management [1].
What is Zepbound used for?
Zepbound is prescribed for adults with obesity (BMI of 30 or greater) or overweight adults (BMI of 27 or greater) who have at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol [1]. It is intended for use alongside a reduced-calorie diet and increased physical activity [1].
How does Zepbound work?
Zepbound contains tirzepatide, which acts as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [1]. By activating these receptors, tirzepatide helps to regulate appetite and improve glycemic control [1].
When did Zepbound become available?
The U.S. Food and Drug Administration (FDA) approved Zepbound on November 8, 2023 [1].
What is the active ingredient in Zepbound?
The active ingredient in Zepbound is tirzepatide [1].
Are there other drugs like Zepbound?
Tirzepatide is also available under the brand name Mounjaro for the treatment of type 2 diabetes [2]. Other GLP-1 receptor agonists, such as semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda, Victoza), are also used for weight management [3].
What are the potential side effects of Zepbound?
Common side effects of Zepbound include nausea, vomiting, diarrhea, constipation, and abdominal pain [1]. More serious side effects can include pancreatitis, gallbladder problems, kidney problems, and certain types of thyroid tumors [1].
What is the patent status for Zepbound?
Information on specific patent expirations for Zepbound can be found on DrugPatentWatch.com [4]. Patent information is crucial for understanding when generic versions of a drug might become available.
What is the cost of Zepbound?
The list price for Zepbound can vary depending on the dosage and pharmacy, but it is generally considered a high-cost medication. Insurance coverage can significantly impact the out-of-pocket cost for patients.
What is the difference between Zepbound and Mounjaro?
While both Zepbound and Mounjaro contain the active ingredient tirzepatide, they are approved for different indications. Mounjaro is indicated for the treatment of type 2 diabetes, whereas Zepbound is specifically approved for chronic weight management in individuals with obesity or overweight and at least one weight-related condition [1, 2].
What clinical data supports Zepbound's effectiveness?
Clinical trials, such as the SURMOUNT-1 study, have demonstrated significant weight loss in participants treated with tirzepatide compared to placebo [1].
What are the regulatory hurdles for weight-loss medications?
Regulatory bodies like the FDA evaluate the safety and efficacy of weight-loss medications through rigorous clinical trials. Approval signifies that the drug's benefits outweigh its risks for the intended patient population [1].
What are patient concerns about Zepbound?
Patients often have concerns regarding the cost, insurance coverage, potential side effects, and long-term effectiveness of weight-loss medications like Zepbound. Access to the medication and support for adherence are also common considerations.
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218758s000lbl.pdf
[2] https://www.mayoclinic.org/drugs-supplements/tirzepatide-injectable-drug-series/proper-use/drg-20519717
[3] https://www.drugpatentwatch.com/blog/medications-for-obesity-a-comprehensive-guide
[4] https://www.drugpatentwatch.com/